Mitrović Zdravko, Aurer Igor
Zavod za hematologiju, Klinika za unutarnje bolesti, Medicinski fakultet i Klinicki bolnicki centar, Zagreb.
Lijec Vjesn. 2006 Jan-Feb;128(1-2):36-42.
Rituximab, a chimeric anti-CD20 monoclonal antibody, has become a part of standard treatment of B-cell non-Hodgkin lymphoma in the last several years. Depleting CD20+ cells by various mechanisms, it is active as a single agent and particularly when combined with chemotherapy. It is effective in "in vivo" elimination of neoplastic cells from the hematopoetic stem cell transplant. Side-effects are mostly infusion related, mild to moderate, mediated by cytokine release. Because of different mechanisms of action, adding rituximab to chemotherapy does not cause additional toxicity. Combination of rituximab and chemotherapy improves response rates in indolent lymphomas and survival in aggressive lymphomas.
利妥昔单抗是一种嵌合型抗CD20单克隆抗体，在过去几年已成为B细胞非霍奇金淋巴瘤标准治疗的一部分。它通过多种机制清除CD20+细胞，作为单一药物有效，尤其是与化疗联合使用时。它在“体内”从造血干细胞移植中有效清除肿瘤细胞。副作用大多与输注相关，程度为轻至中度，由细胞因子释放介导。由于作用机制不同，将利妥昔单抗添加到化疗中不会导致额外的毒性。利妥昔单抗与化疗联合可提高惰性淋巴瘤的缓解率和侵袭性淋巴瘤的生存率。
